Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Saccharomyces boulardii is a probiotic yeast that has been investigated for its potential to support or treat gastrointestinal diseases, including Crohn's Disease. There is some scientific evidence supporting its use, but the overall quality and consistency of the data are moderate at best, which is reflected in the evidence rating of 2 out of 5. Several small randomized controlled trials and meta-analyses have explored the use of S. boulardii in Crohn's Disease, mainly focusing on its ability to maintain remission or reduce the frequency of relapses. For example, a 2000 study by Guslandi et al. suggested that patients receiving S. boulardii alongside mesalazine had a lower relapse rate than those on mesalazine alone. However, subsequent studies have produced mixed results, and the sample sizes have generally been small, limiting the generalizability of the findings. Mechanistically, S. boulardii is thought to exert anti-inflammatory effects, modulate gut microbiota, and enhance intestinal barrier function, which could be beneficial in Crohn's Disease. Nevertheless, major clinical guidelines do not currently recommend S. boulardii as standard therapy for Crohn's Disease due to insufficient evidence. While its use is supported by some preliminary scientific research, more large-scale, high-quality clinical trials are needed to firmly establish its efficacy and safety in this context.

More about Saccharomyces boulardii
More about Crohn's Disease

Other ingredients used for Crohn's Disease

Other health conditions supported by Saccharomyces boulardii

Products containing Saccharomyces boulardii